Davis Robert M 4

What Happened

• Robert M. Davis, Chairman, CEO & President and a director of Merck (MRK), exercised derivative awards on 2026-04-29 that resulted in 13,300 shares being issued to him. The exercise is reported at $110.03 per share (total value ≈ $1,463,399).
• To satisfy tax withholding/tax liability, 6,551 of those shares were withheld/disposed at the same per-share value (≈ $720,807). A related derivative instrument was reported disposed at $0, reflecting the conversion/settlement of the derivative into shares. Net shares retained from this transaction = 6,749.
• This is an acquisition via exercise (a routine executive compensation event) with an accompanying automatic withholding to cover taxes, not an open-market sale signaling a change in investment view.

Key Details

• Transaction date: 2026-04-29; Filing date: 2026-05-01 (appears timely).
• Exercise details: 13,300 shares acquired at $110.03 each (≈ $1,463,399).
• Tax withholding: 6,551 shares withheld/disposed at $110.03 each (≈ $720,807).
• Net shares delivered to insider: 6,749 shares (13,300 − 6,551).
• Footnotes: F1 defines restricted stock units (RSUs) as a contingent right to one share. F2 notes related RSUs vest and will be distributed in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
• Filing does not state total shares owned by the insider after the transaction in the provided summary.

Context

• This was effectively a cashless-style settlement: options/derivatives were converted to shares and some shares were withheld to cover taxes (a common practice for executive awards).
• Such exercises are part of regular compensation and do not by themselves indicate a bullish or bearish signal about the company from the insider.